SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 20,245.90 |
| Book Value / Share | 84.01 |
| Price / Book | n/a |
| NCAV ($M) | 16,766.90 |
| NCAV / Share | 69.57 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.05 |
| Return on Assets (ROA) | 0.04 |
| Return on Equity (ROE) | 0.05 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 9.26 |
| Current Ratio | 9.43 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 19,527.30 |
| Assets | 23,006.30 |
| Liabilities | 2,760.40 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 3,819.00 |
| Operating Income | 969.60 |
| Net Income | 930.30 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 5,371.40 |
| Cash from Investing | -6,954.50 |
| Cash from Financing | -778.60 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Medine GmbH | 17.40 | ||
| 13G/A | Athos Kg | 43.80 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 65,840 | 378,914 | 17.38 | |
| 38,057 | 232,453 | 16.37 | |
| 62,356 | 329,051 | 18.95 | |
| 55,155 | 161,342 | 34.19 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABCL – AbCellera Biologics Inc. | ABOS – Acumen Pharmaceuticals, Inc. |
| ABUS – Arbutus Biopharma Corporation | ACAD – ACADIA Pharmaceuticals Inc. |
| ACLX – Arcellx, Inc. |
Financial data and stock pages provided by
Fintel.io